Background: Neuroendocrine tumors usually present with inoperable metastatic disease and severe hormonal symtoms. Specific chemotherapy, alpha-interferon and the somatostatin analog octreotide are established therapies in these patients but all of them eventually fail. Other somatostatin analogs, e.g., RC-160 and lanreotide, are currently being studied in different doses and modes of administration.
Introduction
Somatostatin analogues, octreotide being the first analogue available for clinical use, have become increasingly important in the management of patients with neuroendocrine gastrointestinal tumors. The rationale for the effect of these agents has been elucidated by the demonstration of somatostatin receptors in 80%-90% of these tumors by autoradiography [1] and octreotide scintigraphy [2] , the latter method having emerged as a major diagnostic tool for staging of the patients, and also as a predictive test for sensitivity to treatment [2] . Most of the analogues presently available for clinical use (octreotide, RC-160, and lanreotide) bind to the somatostatin receptors sstr2 and 5, and in higher doses also to sstr3 [3] , of the sstrl-5 described [4] [5] [6] [7] .
Lanreotide is a synthetic octapeptide structurally related to somatostatin, which has been shown to have antisecretory and antiproliferative effects in vitro and in vivo. The present study, an open pilot phase II study, was conducted to investigate the efficacy and safety of a high dose of lanreotide in patients with advanced neuroendocrine gastrointestinal tumors.
Patients and methods
All 19 patients included in the study had histopathologically confirmed measurable metastatic neuroendocrine gastrointestinal tumors and at least one biochemical tumor marker elevated more than twice the upper limit of normal reference range. Patients were ineligible, if they had received cancer therapy within one month prior to study entry. All patients gave informed consent to participate in the study, which was approved by the ethics committee of the hospital. Patient characteristics are given in Table 1 .
Lanreotide (Henri Beaufour Institute, Washington DC, USA and Ipsen, Paris, France) was given as four daily subcutaneous injections, beginning with 750 ug per day, then escalating every week up to 12,000 ug per day at six weeks, a dose, which was maintained, if tolerated, for 12 months or until tumor progression.
Tumor size was evaluated before, at one, three, six, nine and 12 months by ultrasonography and computerized tomography (CT). Biochemical tumor markers were determined at the same time intervals. An objective tumor response was defined as a > 50% decrease in the product of perpendicular diameters of measurable tumor lesions. No change, tumor size decreased by < 50% or increased by < 25%, and progressive disease, tumor size increased by >25%. A major biochemical response was defined as a > 50% reduction in at least one tumor marker and < 25% increase in the other tumor markers.
Octreotide scintigraphy with [
In-DTPA-D-Phe 1 ]-octreotide was performed according to a previously described method [2] prior to treatment in 18 patients.
Tissue samples obtained by biopsies from metastases were examined by the TUNEL-method [8] and apoptotic indices estimated.
Results
Lanreotide was administered for three weeks up to 48 weeks (mean 33 weeks). Ten patients completed the whole study, whereas nine stopped after three weeks to nine months (median three months), five of whom stopped due to progressive disease with increasing tumor markers and/or tumor size, and the remaining four due to side effects.
Among 15 patients, who were treated for at least three months, one patients (5%) showed > 50% decrease in tumor size at six months, whereas 12 (70%) patients had no change in tumor size for median 12 months.
The study protocol required a four-week wash-out period of previous treatment but in as many as nine patients, the hormonal symptoms were so severe that this proved to be both medically and ethically impossible, which may have affected the baseline assessment of different biochemical tumor markers. The baseline levels and reductions of tumor markers during treatment are indicated in Table 1 . Urinary 5-hydroxyindoleacetic acid (U-5-HIAA) was significantly reduced at six (P = 0.04) but not at 12 months (P = 0.14). Plasma chromogranin was significantly reduced at both six (P -0.039) and 12 months (P -0.013). Eleven out of 19 patients (58%), i.e., seven carcinoids, one non-functioning EPT, the gastrinoma and the glucagonoma patients, showed significant biochemical responses according to our definition. Seven out of 13 patients (54%) had a > 50% reduction in U-5-HIAA (four of them also had >50% reduction in /'-chromogranin) and eight out of 18 (44%) in P-chromogranin. In most patients, these responses were achieved already at one month, remained at three months and six months, then there was a slightly increasing tendency at nine and 12 months. The median duration of biochemical responses was 12 months (range six weeks to 48 months). In this estimation, four responding patients who continued treatment after 12 months of study, were included.
It was not a primary objective of the study to evaluate symptomatic effects, but the score for flushing was significantly reduced early in the study and still borderline significant at 12 months (P -0.06). With regard to diarrhoea, high-dose lanreotide had a dual effect; in some patients treatment had an ameliorating effect, while others developed diarrhoea as a side effect.
Altogether, there were 29 adverse events possibly drug-related reported by 15 patients, as indicated by Table 1 . Four patients discontinued treatment due to adverse events. One patient stopped due to signs of 'cholecystitis' after six weeks of treatment. She had no gall-stones, but the gall-bladder was 'non-functioning' according to ultrasonography. Another patient discontinued because of intense nausea. A third patient stopped the study due to repeated episodes on syncope and weakness, possibly on the basis of cerebral circulatory insufficiency. In this patient, ultrasonography demonstrated occlusion of the right internal carotid artery, and it cannot be excluded that high-dose lanreotide treatment may aggravate circulatory insufficiency in predisposed patients. Except for a reduced sedimentation rate (P = 0.023), increased hemoglobin content (P -0.045), and reduced thyroxin levels (P -0.005) without alteration of TSH, there were no significant alterations in routine laboratory variables. Pulse rate decreased significantly by 8-10 beats/min {P = 0.0078), otherwise vital signs did not change.
Studies of liver biopsies before, at six and 12 months from eight of the patients in this study showed that the number of apoptotic cells increased, being highest at 12 months, in four of five biochemically responding patients with tumor stabilization.
Discussion
This study evaluated the efficacy and tolerance of longterm treatment with a high dose of the somatostatin analogue lanreotide in patients with advanced and progressive neuroendocrine gastrointestinal tumors, most of them previously treated and failing on chemotherapy, interferon and/or octreotide. By octreotide scintigraphy, somatostatin receptors were demonstrated in 17 out of 18 patients prior to treatment.
A significant reduction in tumor size was observed in only one patient (5%), whereas twelve out of 19 patients (70%) showed stabilization. Considering the progressive and advanced stage of the patients, half of them having failed on normal doses of octreotide with or without interferon, stabilization of tumor growth may be indicative of a therapeutic effect. We had, however, expected a higher tumor size response rate, especially since the majority had somatostatin-receptor-positive tumors demonstrated by octreotide scintigraphy, indicating the presence of sstr2, which is considered to mediate the antiproliferative effect of somatostatin analogs, possibly via stimulation of tyrosine phosphatases. Furthermore, an increase in the apoptotic index in four out of five responders may also be indicative of an antitumoral response. Therefore, stabilization of the disease for several months (median 12 months) in these patients with advanced and progressive disease should indicate a true tumor response (antiproliferation) in 75% of patients.
The overall biochemical response rate of 58% with a median duration of 12 months that we achieved in this study is not higher than that obtained with standard doses of octreotide. Again, the fact that we were unable to comply with the protocol requirements of a four-week wash-out period in half of the patients, may have affected baseline levels of biochemical tumor markers and confounded the comparison with levels during treatment.
The frequency of adverse events during the study was rather high and some new, unreported adverse events occurred. They were mainly gastrointestinal and our general feeling is that they were more severe than with regular doses on somatostatin analogs.
The most interesting observation in this study was that high doses of lanreotide appear to induce apoptosis or programmed cell death in the tumors. There was an increased number of apoptotic cells with time and the increase corrrelated with biochemical response [9] and tumor stabilization. Lanreotide as well as octreotide bind with high affinity to sstr2 and 5. Recently, Srikant et al. have shown that apoptosis is mediated by subtype sstr3 [10] . Lanreotide and octreotide also bind to sstr3 but have a 10-fold lower affinity for this receptor than for sstr2 and 5 [3] . This may explain why apoptosis is only seen with high doses but not with regular doses of somatostatin analogues. Interestingly, apoptosis has been proposed to be an important factor in the regression of hormone-dependent tumors after hormonal therapy [11] . Apoptosis can be induced by many anticancer drugs and this process is thought to be one of the regulating processes of tumor progression. In tumors, the balance between cell proliferation and cell death may be disturbed with increased cell proliferation or cell death as a result. The exact role for apoptosis as an antitumoral effect is still unclear.
In conclusion, treatment with high doses of lanreotide in patients with advanced neuroendocrine gastrointestinal tumors did not show higher tumor or biochemical response rates than standard doses of octreotide. However, it should be kept in mind, that half of the patients had been treated with standard doses octreotide and failed before starting high-dose lanreotide. In a recent study with slow release lanreotide, given 30 mg i.m. every two weeks, the biochemical response rate was 42% and there was no tumor response [12] , which seems to be inferior to our results. Although our response rates measured by conventional radiology and hormonal analyses do not support future high-dose therapy in the clinical routine, we could observe interesting biological effects, that need to be further explored, especially in patients treated with high-dose depot formulations of somatostatin analogues and sstr3 specific anlogues, maybe in combination with chemotherapeutic agents.
